Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/184816
Title: | Immune priming using DC- and T cell-targeting gene therapy sensitizes both treated and distant B16 tumors to checkpoint inhibition |
Author: | Wenthe, Jessica Naseri, Sedigheh Hellström, Ann Charlotte Moreno Olié, Rafael Ullenhag, Gustav Alemany Bonastre, Ramon Lövgren, Tanja Eriksson, Emma Loskog, Angelica |
Keywords: | Melanoma Cèl·lules T Melanoma T cells |
Issue Date: | 1-Mar-2022 |
Publisher: | Elsevier BV |
Abstract: | Immune checkpoint inhibitors have revolutionized the treatment of metastatic melanoma, but most tumors show resistance. Resistance is connected to a non-T cell inflamed phenotype partially caused by a lack of functional dendritic cells (DCs) that are crucial for T cell priming. Herein, we investigated whether the adenoviral gene vehicle mLOAd703 carrying both DC- and T cell-activating genes can lead to inflammation in a B16-CD46 model and thereby overcome resistance to checkpoint inhibition therapy. B16-CD46 cells were injected subcutaneously in one or both flanks of immuno-competent C57BL/6J mice. mLOAd703 treatments were given intratumorally alone or in combination with intraperitoneal checkpoint inhibition therapy (anti-PD-1, anti-PD-L1, or anti-TIM-3). Tumor, lymph node, spleen, and serum samples were analyzed for the presence of immune cells and cytokines/chemokines. B16-CD46 tumors were non-inflamed and resistant to checkpoint blockade. In contrast, mLOAd703 treatment led to infiltration of the tumor by CD8(+) T cells, natural killer (NK) cells, and CD103(+) DCs, accompanied by a systemic increase of pro-inflammatory cytokines interferon gamma (IFN-gamma), tumor necrosis factor alpha (TNF-alpha), and interleukin-27 (IL-27). This response was even more pronounced after combining the virus with checkpoint therapy, in particular with anti-PD-L1 and anti-TIM-3, leading to further reduced tumor growth in injected lesions. Moreover, anti-PD-L1 combination also facilitated abscopal responses in non-injected lesions. |
Note: | Reproducció del document publicat a: https://doi.org/10.1016/j.omto.2022.01.003 |
It is part of: | Molecular Therapy - Oncolytics, 2022, vol. 24, p. 429-442 |
URI: | http://hdl.handle.net/2445/184816 |
Related resource: | https://doi.org/10.1016/j.omto.2022.01.003 |
ISSN: | 2372-7705 |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
PIIS2372770522000079.pdf | 1.01 MB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License